Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Captainblkon Dec 27, 2019 3:35pm

82 Views

Post# 30495101

RE:RE:Massive short covering took place Dec 1-15

Captainblk wrote:
neat find. I haven't believed they were a trapped short for a while now, TBH. I think they may be connected to an interested party/buyer who is trying to either stifle interest in the company from other prospective buyers, or maintain a lower SP for leveraging a better position

also because I don't believe anyone would go to such efforts for free.

Bullboard Posts

Who, why, and what of the great "Crypto Surge"